The FDA has approved apixiban (Eliquis), an oral tablet used to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation (AFib) that is not caused by a heart valve problem. According to the FDA, the safety and efficacy of apixiban in treating patients with AFib not caused by cardiac valve disease were studied in the ARISTOTLE trial, a clinical trial of more than 18,000 patients that compared apixiban with the anti-clotting drug warfarin. In the trial, patients taking apixiban had fewer strokes than those who took warfarin. Apixiban joins other oral anticoagulants dabigatran and rivaroxaban, which have also been approved for this indication. According to the FDA, patients with prosthetic heart valves or with AFib caused by a heart valve problem should not use apixiban as these patients were not studied in a clinical trial.
http://www.fda.gov/NewsEvents/Newsroom/ ... 333634.htm
P.S. Еще одна попытка найти альтернативу "крысиному яду"!
